Cancer Drug

AstraZeneca receives CDSCO's approval to market cancer drug in India

AstraZeneca Pharma on Tuesday said it has received approval from the national drug regulator to market a cancer treatment drug in the country. The company has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import, market, and distribute Trastuzumab Deruxtecan for an additional indication in India, the drug firm said in a statement. With this approval, Trastuzumab Deruxtecan is now indicated for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumours, who have received prior systemic therapy and have no satisfactory alternative treatment options, it added. This marks the first and only antibody drug conjugate in India with a tumour-agnostic indication, representing a significant advancement in precision oncology, the company said. "This milestone reflects our unwavering commitment to patient-centricity, scientific excellence, and equitable access to breakthrough therapies. By bringing Trastuzumab Deruxtecan to ..

Glenmark arm inks $700 million licensing deal with US-based AbbVie

IGI Therapeutics, a wholly owned subsidiary of Glenmark, has licensed its cancer and autoimmune drug ISB 2001 to AbbVie for an upfront payment of $700 million

Cipla gets USFDA nod to market generic version of cancer drug Abraxane

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for paclitaxel protein-bound particles for injectable suspension (albumin-bound), 100 mg/vial, single-dose vial, Cipla said in a regulatory filing. Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial. Protein-bound paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas. The product is expected to be launched in the first half of the current fiscal year in the US, the Mumbai-based drugmaker said. Shares of the company were trading 2.73 per cent up at Rs 1,454.90 apiece on the BSE.

Study shows bacterial vaccine may serve as cancer immunotherapy treatment

The bacterial vaccine proved to be particularly more efficacious than peptide-based therapeutic cancer vaccines

3 cancer drugs now exempt from customs duty; X-ray tubes to become cheaper

The Union minister also brought down the customs duty on X-ray tubes used in medical X-ray machines

State regulators asked to withdraw marketing of cancer drug Olaparib

Manufacturer AstraZeneca Pharma India says its study shows drug may have detrimental effect

Many cancer drugs remain unproven 5 yrs after accelerated approval: Study

The U.S. Food and Drug Administration's accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients' lives? In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within five years. Five years after the initial accelerated approval, you should have a definitive answer, said Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research. Thousands of people are getting those drugs. That seems a mistake if we don't know whether they work or not." The program was created in 1992 to speed access to HIV drugs. Today, 85% of accelerated approvals go to cancer drugs. It allows the FDA to grant early approval to drugs that show promising initial results for treating debilitating or fatal diseases. In exchange, drug companies are expected to do rigorous testing and produce

Rs 100 tablet to prevent resurgence of cancer: All you need to know

This new pill will reduce the side effects of cancer treatment like chemotherapy by about 50 per cent and the chances of getting cancer for a second time by 30 per cent

Alembic Pharmaceuticals gets USFDA nod to market generic cancer drug

The company's product is therapeutically equivalent to AstraZeneca UK's Calquence Capsules (100 mg)

Lupin gets USFDA approval to market generic cancer treatment drug

Lupin on Monday said it has received a tentative approval from the US health regulator to market Dasatinib tablets, used to treat certain types of cancer, in America. The company in partnership with Pharmascience Inc. has received approval from the US Food and Drug Administration (FDA) for Dasatinib tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, it said in a statement. The Mumbai-based drug maker's product is a generic version of Bristol-Myers Squibb Company's Sprycel tablets. As per IQVIA MAT data, Dasatinib tablets had an estimated annual sale of USD 1,569 million in the US. Shares of Lupin settled at Rs 662.50 apiece, up 1.49 per cent on the BSE.

Zydus Cadila gets tentative approval from USFDA to market cancer drug

Drug firm Zydus Cadila on Wednesday said it has received tentative approval from the US health regulator to market Ibrutinib tablets used in the treatment of certain types of cancers.

Cipla settles blood cancer drug litigation with Bristol Myers in US

As it takes away the legal overhang, Cipla can launch the drug once its ANDA is approved

AstraZeneca agrees to pay Japan's Daiichi $6 bn for new cancer drug

The UK drugmaker will pay Japan's Daiichi $1 billion upfront to jointly develop and bring to market a cancer therapy in early clinical tests called DS-1062, the companies said

Cancer drug: Roche, Blueprint ink $1.7-bn deal after gene testing advances

US company Blueprint, which has been working with Roche since 2016, could also receive up to $927 million in milestone payments, plus royalties on sales outside the United States

Dr Reddy's launches cancer drug Abiraterone Acetate in US market

The drug is a therapeutic equivalent generic version of Zytiga owned by Johnson & Johnson

How a residential home provider is coming to aid of child cancer patients

The study has found that the environment plays a statistically significant role in outcomes of cancers like acute leukaemia which need intensive treatment

Cancer now a bigger killer than heart diseases in rich nations: Study

It determined that people in poorer nations were on average 2.5 times more likely to die from heart disease than those in richer ones

A drug that can cure cancer without chemotherapy and side effects!

The complex biological medicines, called antibody drug conjugates (ADCs), have been in development for decades

NPPA slashes prices of 390 cancer drugs; move to benefit 22 lakh patients

All companies have been asked to ensure that the price caps are adhered to.

Govt slashes price of 390 non-scheduled cancer medicines by up to 87%

This move is expected to benefit 22 lakh cancer patients in the country and would result in annual savings of around Rs 800 crore to the patients